N-Butyl-N'-methyl-formamidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Butyl-N'-methyl-formamidine
• 英文别名: N-butyl-N'-methylmethanimidamide
• 化学式: C₆H₁₄N₂
• mdl: MFCD20617083
• 分子量: 114.191
• InChiKey: DDJPHVCNQNVJFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  正丁胺 、 N-Methyl-formimidiumsaeure-methylester-methylsulfat 以 苯 为溶剂， 生成 N-Butyl-N'-methyl-formamidine
  参考文献：
  名称：

  Bredereck,H. et al., Chemische Berichte, 1965, vol. 98, p. 2887 - 2896

  摘要：

  DOI：

文献信息

• Crf antagonists and heterobicyclic compounds
  申请人：Nakai Hisao

  公开号：US20070027156A1

  公开（公告）日：2007-02-01

  CRF antagonists comprising as an active ingredient, the compound of formula (I) wherein A ring is 5-6 membered mono-cyclic ring which may be substituted; B ring is 5-7 membered unsaturated mono-heterocyclic ring which may be contained another 1-2 of hetero atom(s) and substituted by another substituents; W 1 and W 2 is carbon atom or nitrogen atom; Z is NR 3 , oxygen atom, sulfur which may be oxidized or CR 4 R 5 ; R 1 is alkyl, alkenyl or alkynyl that may be substituted, amino which may be protected, hydroxyl which may be protected, S(O) n R 6 , COR 7 , or cyclic group which may be substituted; R 2 is unsaturated cyclic group which may be substituted.

  CRF拮抗剂包括化合物(I)作为活性成分，其中A环是5-6成员单环，可以被取代；B环是5-7成员不饱和单杂环，可能包含另外1-2个杂原子，并被另外的取代基取代；W1和W2是碳原子或氮原子；Z是NR3、氧原子、硫，可以被氧化或CR4R5取代；R1是烷基、烯基或炔基，可以被取代，氨基可以被保护，羟基可以被保护，S（O）nR6、COR7或环状基团可以被取代；R2是不饱和环状基团，可以被取代。
• Bredereck,H. et al., Angewandte Chemie, 1963, vol. 75, p. 790 - 791
  作者：Bredereck,H. et al.

  DOI：——

  日期：——
• [EN] ENZYME INHIBITORS<br/>[FR] INHIBITEURS ENZYMATIQUES
  申请人：[en]KALVISTA PHARMACEUTICALS LIMITED

  公开号：WO2022118016A2

  公开（公告）日：2022-06-09

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, R5, n, Z, X, Y and B are as defined herein. The present invention also relates to compounds useful as synthetic intermediates of compounds of formula (I).